Trials / Completed
CompletedNCT00545311
Safety and Tolerability of Multiple Inhaled NVA237 Doses in Chronic Obstructive Pulmonary Disease (COPD) Patients
A Multi-Center, Randomized, Double-Blind, Parallel-Group Study to Investigate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Multiple Inhaled NVA237 Doses at Four Dose Levels in COPD Patients
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- Novartis · Industry
- Sex
- All
- Age
- 40 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the pharmacokinetics, pharmacodynamics and safety of multiple doses of the NVA237 in mild and moderate COPD patients .
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | NVA237 | |
| DRUG | NVA237 | |
| DRUG | NVA237 | |
| DRUG | NVA237 | |
| DRUG | Placebo |
Timeline
- Start date
- 2007-07-01
- Completion
- 2007-10-01
- First posted
- 2007-10-17
- Last updated
- 2008-01-08
Locations
4 sites across 2 countries: Denmark, Germany
Source: ClinicalTrials.gov record NCT00545311. Inclusion in this directory is not an endorsement.